Skip to main content
. 2019 Oct 3;4(19):e129183. doi: 10.1172/jci.insight.129183

Figure 4. SMC CYB5R3 acts as an sGC heme reductase in the context of Ang II–induced systemic hypertension.

Figure 4

(A) Ex vivo wire myography experiments on mesenteric arteries from WT (n = 9–12, gray) and SMC CYB5R3–KO mice (n = 10–12, red) after 14 days Ang II (750 ng kg–1 min–1) treatment. (B) SMC CYB5R3–KO mice have increased U46619-mediated vasoconstriction than WT mice. P values determined by 2-tailed, unpaired t test. (C) SMC CYB5R3–KO mice are significantly less responsive to acetylcholine than WT mice. (D) WT mice are more responsive to vasodilator SNP than SMC CYB5R3–KO mice. (E) SMC CYB5R3–KO mice are more responsive than WT mice to BAY 58-2667. (C–E) P values represent statistical differences between WT and SMC CYB5R3–KO by 2-way ANOVA with *P < 0.05 representing significance by post hoc Sidak multiple comparison tests. Error bars are ± SEM.